Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
620 hedge funds and large institutions have $21.5B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2022 Q1 according to their latest regulatory filings, with 86 funds opening new positions, 257 increasing their positions, 212 reducing their positions, and 70 closing their positions.
100% more call options, than puts
Call options by funds: $156M | Put options by funds: $78M
29% more funds holding in top 10
Funds holding in top 10: 21 → 27 (+6)
23% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 70
21% more repeat investments, than reductions
Existing positions increased: 257 | Existing positions reduced: 212
1% more funds holding
Funds holding: 611 → 620 (+9)
1% less capital invested
Capital invested by funds: $21.8B → $21.5B (-$301M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$690M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$98.8M |
| 3 |
BlackRock
New York
|
+$80.7M |
| 4 |
Goldman Sachs
New York
|
+$78.6M |
| 5 |
SC
Samlyn Capital
New York
|
+$76.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$272M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$152M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$136M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$101M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$97.3M |
HZNP Hedge Fund Activity: Q1 2022 in Review
620 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2022, worth a combined $21.5B — down 1.4% from $21.8B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new HZNP positions and 70 closed out — a net gain of 16 holders — while 257 added to existing stakes and 212 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $690M. The largest seller was Avoro Capital Advisors, cutting an estimated $272M.
- 620 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2022, up from 611 in Q4 2021.
- Funds reported $21.5B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2022, down 1.4% quarter-over-quarter.
- 86 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2022 and 70 closed out, a net change of +16 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2022 was Capital International Investors, an estimated $690M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2022 was Avoro Capital Advisors, an estimated $272M sold.
Based on aggregated 13F filings for Q1 2022.